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ABSTRACT
Introduction: Parenteral antimony-based compounds are still the standard of care for cutaneous leishmaniasis (CL) treatment in 
many countries, despite their high toxicity. Previous studies showed that oral azithromycin could be an option for CL treatment. 
The aim of this study was to evaluate efﬁ cacy and safety of oral azithromycin (AZ) for CL treatment compared with injectable 
meglumine antimoniate (MA). Methods: This was a randomized, open-label, 2-arm, non-inferiority clinical trial. Treatment-
naïve patients with localized CL were treated with MA (15mg/kg/day up to 1,215mg) or AZ (500mg/day) during 20 consecutive 
days. The primary efﬁ cacy end point was a CL cure 90 days after treatment completion. The analysis was performed with 
intention-to-treat (ITT) and per protocol (PP) analyses. After an anticipated interim analysis, the study was interrupted due to the 
high failure rate in the azithromycin group. Results: Twenty-four volunteers were included in each group. The MA group had a 
higher cure rate than the AZ group with the ITT and PP analyses, which were 54.2% versus 20.8% [relative risk (RR) 1.97; 95% 
conﬁ dence intervals (95%CI) 1.13-3.42] and 72.2% versus 23.8% (RR 3.03; 95%CI 1.34-6.87), respectively. No unexpected 
adverse events were observed. Conclusions: Azithromycin is ineffective for CL treatment and does not seem to have a role in 
the therapeutic arsenal for CL.
Keywords: Azithromycin. Cutaneous leishmaniasis. Leishmania braziliensis. Randomized controlled trial. 
Meglumine antimoniate.
Cutaneous leishmaniasis (CL) is a serious public health 
problem, with approximately 0.69 to 1.2 million new cases 
occurring per year worldwide1. Ten countries, including 
Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, 
North Sudan, Costa Rica and Peru, together account for 70 to 
75% of the global estimated CL incidence1. In Brazil, from 2008 
to 2012, a mean of 21,736 new cases per year of tegumentary 
leishmaniasis were reported2. CL may manifest as single 
or multiple skin lesions, which occur in the same region or 
disseminated in different body regions, and can have a severe 
impact on the patient’s quality of life3,4. 
Cutaneous leishmaniasis treatment accelerates cures, reduces 
scarring and relapses, and it is expected that it may reduce the 
frequency of disease dissemination to the upper airway mucosal 
surfaces. Parenteral antimony is still the standard of care in many 
countries. However, the once daily intramuscular or intravenous 
injection over 20 days normally causes discomfort to patients and 
it is difﬁ cult to administer in some poorly resourced countries or 
regions. Moreover, antimony-based compounds are toxic drugs 
and may cause serious and life-threatening events, such as acute 
pancreatitis and cardiac arrhythmias. Frequently, patients have 
formal contraindications to antimony use, such as uncontrolled 
diabetes mellitus, liver or heart disease, and chronic kidney disease. 
These conditions are more common in older patients, appearing 
after a few days of drug administration and when higher doses 
are required. Other treatment options include pentamidine and 
amphotericin B, which are both injectable and have a safety proﬁ le 
that is similar to antimony and the lipid formulations of amphotericin 
B, wich are expensive optionsfor the majority of the CL endemic 
countries. Various studies evaluated oral drugs as candidates for CL 
treatment, such as miltefosine5-7, ﬂ uconazole8,9, and azithromycin10-15, 
with controversial results or no clear evidence of efficacy.
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METHODS
Azithromycin, an azalide antibiotic is largely used to treat 
bacterial infections, and was identiﬁ ed as a potential option 
for CL treatment due to its wide tissue distribution and high 
intracellular concentration, including macrophages16. Three 
studies showed that azithromycin was active against Leishmania 
parasites. Krolewiecki et al17 showed both in vitro and in vivo 
activity of azithromycin against Leishmania (Leishmania) 
major promastigote and amastigote forms17. Tanyuksel et al18 
demonstrated in vitro the potential leishmanicidal effect of 
azithromycin on intracellular amastigote L. (L.) major forms in 
peritoneal macrophages from mice18. Lastly, Oliveira-Silva et al16. 
showed that azithromycin was active in vitro against Leishmania 
(Leishmania) amazonensis, Leishmania (Viannia) braziliensis, 
and Leishmania (Leishmania) chagasi and suggested that the drug 
might offer an alternative to current leishmaniasis treatments16.
Despite these promising in vitro results, clinical studies 
of azithromycin and CL had controversial results. Prata 
et al.13 showed a cure rate of 85% in an open non-controlled 
trial with 20 patients13. Four studies in Brazil showed low 
efﬁ cacy of azithromycin when compared with meglumine 
antimoniate10,14,15. Two others studies evaluated azithromycin 
against Old World leishmaniasis, both with poor responses11,12. 
These studies enrolled a small number of volunteers, 22 to 49, 
with varied clinical protocols, restraining a deﬁ nitive conclusion 
regarding the possible role of azithromycin as a therapeutic 
option for CL. The aim of this study was to evaluate the efﬁ cacy 
and safety of oral azithromycin for CL treatment compared with 
injectable meglumine antimoniate.
Study population
Treatment-naïve patients with localized cutaneous leishmaniasis 
were included in the study after signing the informed consent form 
if they met the following inclusion criteria: 1) age between 14 to 65 
years; and 2) ≤ 6 apparent cutaneous lesions that were compatible 
with CL and a positive Montenegro reaction test (≥5mm), followed 
by parasitological or molecular conﬁ rmation of the CL infection 
(which included a direct exam, culture, pathological exam, and/or 
kinetoplast deoxyribonucleic acid (kDNA) detection by polymerase 
chain reaction). L. (Viannia) braziliensis was the species identiﬁ ed 
in deoxyribonucleic acid (DNA) samples extracted from biopsy 
fragments of 29 patients. Leishmania (Viannia) braziliensis is the 
most common species found in the patients at the study reference 
center (>90%) (unpublished data) and in the study-area (92.5%)19. 
Patients who had or met one of the following criteria were 
not eligible to participate: disseminated leishmaniasis; the 
presence of mucosal lesions; pregnancy [conﬁ rmed by beta 
human chorionic gonadotropin (β-hCG) in their blood sample]; 
breast feeding; diseases that interfere with scar healing; primary 
or acquired immunodeﬁ ciency; immunosuppressive drug use; 
use of any topical or oral medication that could interfere with the 
healing process or with potential leishmanicidal action, including 
antibiotics; decompensated chronic diseases; any electrocardiogram 
(ECG) abnormalities that contraindicated meglumine antimoniate 
use; use of any medication that could prolong the QTc interval; 
any diseases or conditions that may lead to non-compliance to 
protocol, including alcohol abuse; and intolerance to azithromycin, 
macrolides or meglumine antimoniate.
Study design
This multicenter, randomized, open-label, 2-arm parallel 
group, non-inferiority clinical trial was conducted in two 
leishmaniasis reference centers: The René Rachou Research 
Centre/Oswaldo Cruz Foundation (CPqRR/FIOCRUZ), and 
Montes Claros State University (Unimontes). Both centers are 
located in Minas Gerais, Brazil. Randomization used blocks 
of six and a 1:1 allocation rate were generated by using the 
Web site Randomization.com [http://www.randomization.
com]. Envelopes that were sequentially numbered, opaque and 
sealed were provided to the local clinical coordinator. Allocation 
followed the recruitment sequence, and the patient’s name was 
written on the envelope before it was opened.
Eligible patients were allocated into one of the two 
treatment arms: Group A (meglumine antimoniate) or group B 
(azithromycin). The group A patients were treated, according to 
the Brazilian Ministry of Health recommendation, with 15mg/
kg/day of intravenous or intramuscular meglumine antimoniate 
(maximum daily dose of 1,215mg) over 20 consecutive days 
(Glucantime® - Aventis, batch number: 605022). The group 
B patients were orally treated with one 500mg azithromycin 
tablet per day over 20 consecutive days (Zitromax® - GSK, 
batch numbers 6186401403; 0864009). All of the treatments 
were performed in an ambulatory setting.
Treatment adherence for both treatment groups was 
supervised daily by the health professionals of the public 
ambulatory unit that was closest to each patient’s home. 
Additionally, all of the drug administration was registered in a 
speciﬁ c form and signed by the health professional under close 
supervision of the study team.
Treatment was considered incomplete if it was interrupted 
before the 16th dose or if the treatment lasted for more than 
30 days. A treatment was considered irregular if there was an 
interval greater than 72h between any drug doses.
Safety and efﬁ cacy evaluations
Clinical evaluations, which included vital signs and 
laboratory tests, (including complete blood cell counts, 
biochemistry tests, urinalysis, and a 12-lead ECG) were assessed 
at enrollment, during treatment (days 5, 10, and 20), and 10 
days after treatment. A clinical evaluation was also performed 
at months 1, 2, 3, and 6 after treatment. The lesion areas were 
measured using a 0.1 cm precision caliper, and the following 
formula was applied: D1 x D2 x π/4, where D1 and D2 are the 
greatest and smallest diameters, respectively. Photographs were 
taken to record the lesion evolution. 
To assess safety, clinical and laboratorial adverse events 
were investigated on an outparient basis. The participants were 
withdrawn from the study if the patient presented with a severe 
or life threatening event or if the investigator was concerned 
about treatment safety. 
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The primary efficacy end point was CL cure rate by 
intention-to-treat (ITT) and per protocol (PP) analyses. A cure 
was deﬁ ned as complete lesion healing and re-epithelialization 
without inﬂ ammatory inﬁ ltration and erythema until 90 days 
after the treatment ended. Patients withdrawn from the study due 
to AEs or loss to follow-up were considered treatment failures 
in the ITT analysis.
The secondary endpoints were as follows: a delayed CL cure 
(180 days after treatment), CL recurrence between cure and 
180 days after treatment, and the percentage of healed lesions 
at the end of treatment and at 30, 60, and 90 days after the 
treatment ended. Recurrence was deﬁ ned by the reappearance 
of a previous lesion or a new cutaneous or mucosal lesion. 
Patient lost to follow-up were considered as recurrences in 
the ITT analysis. All of the secondary efﬁ cacy endpoints were 
analyzed by ITT and per protocol (PP).
The safety analysis included all patients who received 
at least one dose of study drugs. Clinical, laboratory and ECG 
abnormalities were categorized according to the acquired 
immunodeficiency syndrome (AIDS) clinical trial group 
(ACTG) criteria. 
Patients who did not respond to azithromycin were treated 
with the standard therapy with meglumine antimoniate, the same 
regime of the group A arm, or second-line drugs, if necessary.
Statistical analysis
Initially, a sample size of 310 patients in each group was 
calculated using an accuracy method, with an alpha error = 0.05 
and a power = 0.8, and considering a 60% cure rate in both arms. 
The inferior limit of the 95% conﬁ dence interval (one-sided) 
between the azithromycin and meglumine antimoniate cure rates 
should not have been less than -10% in order to consider the 
azithromycin treatment as non-inferior. The ﬁ nal sample size 
was 682 patients, which took into consideration a possible loss 
of follow-up period of 10%.
The data were summarized as frequencies and percentages 
for categorical variables and as the means ± standard deviation 
(SD) for continuous variables. Fisher’s exact test (two-sided) 
and a two-sample t-test were used to compare the differences 
between the groups for the categorical and continuous variables, 
respectively. P-values lower than 0.05 were considered 
statistically signiﬁ cant. The statistical analysis was made using 
the Statistical Package for the Social Sciences (SPSS) Statistics 
software - version 19 (IBM, US).
Due to the high failure rate in the azithromycin group, the 
principal investigator, in accordance with the Institutional 
Sponsor, requested an evaluation of an external ad-hoc 
Review Board, which recommended a trial interruption. No 
new inclusions were conducted and the enrolled patients were 
followed according to the protocol.
Ethical considerations
The clinical study protocol and informed consent were 
reviewed and approved by the Rene Rachou Research 
Centre, Oswaldo Cruz Foundation [Centro de Pesquisa René 
Rachou, Fundação Oswaldo Cruz (CPqRR, FIOCRUZ)], 
(CAAE 0010.0.246.000-06/CEPSH-CPqRR 20/2006) and 
Montes Claros State University - Unimontes (Comitê de Ética 
em Pesquisa da Universidade Estadual de Montes Claros 2050) 
ethics committees. The Brazilian National Council on Ethics 
in Research (CONEP) accredits these committees. The project 
has also been approved by the Ethics Review Committee of the 
University of Brasilia from where a third trial site was expected 
to be coordinated but was cancelled due to the study interruption. 
The clinical study was conducted in accordance with the Good 
Clinical Practice (ICH 1996) and Brazilian National Health 
Council (CNS) resolutions 196/1996 and 251/1997. The study 
is registered at www.Clinicaltrials.gov (NCT00682656). 
Written informed consent was obtained for every subject prior 
to enrollment. For patients younger than 18 years of age, a 
written informed consent was also obtained from their legal 
representative. All of the subjects were informed about the 
nature of the trial and possible risks bound to it and that they 
were free to withdraw the consent of participation at any time. 
The investigators and study staff observed the conﬁ dentiality of 
the records.
Seventy-seven patients were screened and 48 volunteers 
with conﬁ rmed CL were enrolled between August/2008 and 
September/2011. These included 43 subjects at Belo Horizonte 
and ﬁ ve at Montes Claros. The last 6-month follow-up visit was 
conducted on March 2012.
Table 1 shows the baseline demographic and clinical 
characteristics. The majority of the subjects were male 
(38 - 79.2%), their ages ranged from 15 to 56 years (mean 
34.5 ± 12.2), and their years of schooling ranged from 2 to 17 years 
(mean 8.3 ± 3.7). Almost 2/3 of the patients had only one lesion, 
and the time since the ﬁ rst lesion occurred ranged from 15 to 425 
days (mean 98.6 ± 67.5). Additionally, the lesions of 29 (61.7%) 
patients had ≤ 90 days of progression. The mean lesion area was 
5.17 cm2 (SD =10.11). There were no baseline demographic 
and clinical characteristic differences between both groups .
Figure 1 shows the participants treatments and their follow-
ups. Twenty-four participants were enrolled in each treatment 
group. Four subjects from the meglumine antimoniate group 
withdrew during treatment due to adverse events. All of the 
patients enrolled in the azithromycin group completed their 
treatment. During the 3 months post-treatment, ﬁ ve patients were 
lost to follow-up, which included three from the azithromycin 
group and two from the meglumine antimoniate group. Six 
patients were initially considered as failures; however, they 
were cured between 3 and 6 months after their treatments ended. 
These included two in the azithromycin group and four in the 
meglumine antimoniate group (Figure 1). 
Table 2 shows the primary and secondary efﬁ cacy endpoints. 
Three months after the end of the treatments, the meglumine 
antimoniate group had a higher cure rate than the azithromycin 
group in the ITT and PP analyses, (54.2% versus 20.8% 
[relative risks (RR) 1.97; 95% conﬁ dence intervals (95%CI) 
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TABLE 1 - The baseline demographic and clinical characteristics of each group.
                           Meglumine antimoniate  Azithromycin 
                   Group A (n=24) Group B (n=24)         Total (n=48)
Variables n % n % n %
Male - N (%) 19 79.2 19 79.2 38 79.2
Mean age - years (SD) 34.5  11.7 34.4  13.1 34.5  12.2
Mean years of schooling (SD) 8.6  3.4 7.9  4.1 8.3  3.7
Mean lesion number (SD) 1.9  1.2 1.3 0.8 1.6  1.0
One lesion N (%) 12  50.0 19  79.2 31  64.6
Lesion area - cm2 (SD)  6.11  13.22 3.95  2.93 5.17  10.11
Mean time (days ) since ﬁ rst lesion (SD) 109.2  85.3 87.6  41.0 98.6  67.5











































FIGURE 1 - Enrollment, treatment, and follow-up of the study subjects. ITT: intention-to-treat; PP: per protocol.
1.13-3.42] and 72.2% versus 23.8% [RR 3.03; 95%CI 1.34-
6.87], respectively). Similar results were observed with the late 
cure rate (6 months after the end of the treatments). Four cured 
patients were lost to follow-up between 3 and 6 months after 
treatments. No clinical recurrence was documented among the 
patients who effectively returned for their last follow-up visit.
As shown in Table 3, considering the cured patients, despite 
the the higher percentage of healed lesions when the treatment 
was completed and 30 days after treatment completion in 
the meglumine antimoniate group, there were no signiﬁ cant 
differences between the groups regarding healing speed.
No unexpected adverse events (AE) were observed during 
the study. A total of 24 patients reported 62 AEs that were 
possibly related or related with the study drugs, [15 (62.5%) 
in the meglumine antimoniate group and nine (37.5%) in the 
azithromycin group (p=0.039; RR=2.188 - 95%CI 1.040-
4.603)]. The AEs were more frequent in the meglumine 
antimoniate group (49 events) compared with the azithromycin 
group (13 events). Regarding severity, the majority (51/62; 
82.5%) of the AEs were considered mild; however, nine (14.5%) 
were moderate and two (3.2%) were severe (e.g., malaise and 
vomiting). There were no signiﬁ cant differences between the 
Toledo Jr A et al. - Poor response to azithromycin in CL
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TABLE 3 - The percentage of healed lesions at treatment completion and at days 30, 60 and 90 after treatment completion.
 Meglumine antimoniate (n=13) Azithromycin (n=5)
 Group A Group B  
Time n % n % p*
End of treatment 1 7.7 0 0.0 <0.001
30 days post-treatment 8 61.5 1 20.0 >0.05
60 days post-treatment 12 92.3 4 80.0 >0.05
90 days post-treatment 13 100.0 5 100.0 >0.05
*Fisher’s exact test (2-sided).
TABLE 2 - Primary and secondary study endpoints.
                 Meglumine antimoniate Azithromycin  
              Group A                     Group B
Endpoint n % n % p-value* RR (95%CI)
Cure 3 months after treatment (ITT) 13/24 54.2 5/24 20.8 0.036 1.97 (1.13-3.42)
Cure 3 months after treatment (PP) 13/18 72.2 5/21 23.8 0.004 3.03 (1.34-6.87)
Cure 6 months after treatment (ITT) 16/24 66.7 7/24 29.2 0.20 2.17 (1.16-4.09)
Cure 6 months after treatment (PP) 16/17 94.1 7/21 33.3 <.001 10.4 (1.54-70.7)
RR: relative risk; 95%CI: 95% conﬁ dence interval; ITT: intention-to-treat; PP: per protocol. *Fisher’s exact test (2-sided).
groups. No life threatening conditions were observed during 
the treatments. The AEs were diverse between the groups 
(Table 4). The most frequent AEs in the meglumine antimoniate 
group were myalgia (22.4%), arthralgia (18.4%), and malaise 
(8.1%). In the azithromycin group, they were diarrhea (30.8%) 
and abdominal pain (23.1%).
DISCUSSION
Until now, few studies have tested azithromycin as an 
alternative treatment for CL10-12,14,15. Only one study was a 
randomized clinical trial that compared oral azithromycin and 
meglumine antimoniate for the treatment of CL in Americas, 
which included 23 patients in each study group. The authors 
concluded that azithromycin had a moderate efﬁ cacy against 
L. (V.) braziliensis (45.5%) and suggested that a subset of 
patients could beneﬁ t from this therapeutic option10.
Nonetheless, a number of reasons supported the decision 
to compare oral azithromycin and meglumine antimoniate in 
Brazil and to design a larger randomized non-inferiority trial 
to test a cure rate difference of not less than -10% that could 
allow the registration of a new use for azithromycin by the 
Brazilian regulatory agency [Agência Nacional de Vigilância 
Sanitária (ANVISA)]. It is a consensus that new treatments 
are urgently needed to improve adherence, cost, cure rates, 
safety and quality of life. Additionally, there is a concern 
regarding antimoniate resistance and the need of a safer and 
better-tolerated treatment20,21. Azithromycin is an oral and well-
tolerated drug with the important advantage of low cost, and 
oral treatments could improve access and adherence. Moreover, 
if a moderate efﬁ cacy was to be proven, further analysis could 
identify subsets of patients to whom an oral, less expensive and 
safer drug could be ﬁ rst offered.
Unfortunately, the high clinical failure rate of azithromycin 
led to the premature interruption of this study. Even with 
the small number of patients included until the study interruption, 
the analysis was able to show the inferiority of azithromycin 
compared with meglumine antimoniate in the ITT and PP 
analyses. 
The dosing regimen for azithromycin was chosen to allow 
the comparison with the standard schedule of meglumine 
antimoniate at a dose with predictable good tolerance for the 20 
days treatment, a longer duration than the usual prescription for 
bacterial infections. Krolewiecki et al.10 used azithromycin for 
28 days: one gram in the ﬁ rst day and 500mg for the following 
27 days. A second cycle at the same doses and lasting 15 days 
was indicated for patients with clinical improvement without 
resolution 14 days after completing the ﬁ rst cycle. This dosing 
difference and the geographical parasite and/or host speciﬁ cities 
may have contributed for the slight higher cure rate observed 
by those authors compared with our observed cure rate (45.5% 
vs. 33.3%)10.
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TABLE 4 - Adverse events related or possibly related to the study drugs.
 Meglumine antimoniate Azithromycin
 Group A Group B Total
Adverse event n % n % n %
Myalgia 11 22.4 0 0.0 11 17.7
Arthralgia 9 18.4 0 0.0 9 14.5
Nausea/vomits 5 10.2 2 15.4 7 14.5
Malaise 5 10.2 0 0.0 5 8.1
Headache 4 8.2 0 0.0 4 6.5
Diarrhea 0 0.0 4 30.8 4 6.5
Pain in the arms 4 8.2 0 0.0 4 6.5
Abdominal pain 0 0.0 3 23.1 3 4.8
Constipation 0 0.0 2 15.4 2 3.2
Gastric discomfort 0 0.0 2 15.4 2 3.2
Others 11 22.1 0 0.0 11 17.7
Total 49 100.0 13 100.0 62 100.0
The number of patients presenting AEs and the frequency of 
those effects were higher in the group treated with meglumine 
antimoniate, although the severity grade was deﬁ ned as mild for the 
large majority in both groups. In the azithromycin group, there were 
a predominance of gastrointestinal  AEs and more diverse systemic 
effects were observed in the meglumine antimoniate group.
In conclusion, the present study showed that azithromycin 
is not effective in CL treatment in an area where L. braziliensis 
is the predominant parasitic species and does not seem to have 
a role in the therapeutic arsenal for CL in this particular setting. 
A careful evaluation should be mandatory for future decision 
making on the need of new clinical trials using azithromycin 
alone or in combination with other drugs for CL.
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